Shire Adds Phase III Ophthalmology Asset to Pipeline with SARcode Bioscience Purchase
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 4 (Table of Contents)
Published: 11 Apr-2013
DOI: 10.3833/pdr.v2013.i4.1920 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Consistent with its recent move into ophthalmology and its small biotech acquisition strategy, Shire has agreed to acquire SARcode Bioscience and its lead asset lifitegrast (SAR 1118), a Phase III drug candidate for the signs and symptoms of dry eye syndrome...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS